about
A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent CohortsThrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients.Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort studyClassification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria.The attributable mortality of delirium in critically ill patients: prospective cohort study.Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study.Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients.Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis.Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome.Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients.Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review.Association of Gender With Outcome and Host Response in Critically Ill Sepsis Patients.Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study.An Unbalanced Inflammatory Cytokine Response Is Not Associated With Mortality Following Sepsis: A Prospective Cohort Study.Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis; a case control study.Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients.Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis.Epidemiology, Management, and Risk-Adjusted Mortality of ICU-Acquired Enterococcal Bacteremia.Electronic implementation of a novel surveillance paradigm for ventilator-associated events. Feasibility and validation.The Host Response in Patients with Sepsis Developing Intensive Care Unit-acquired Secondary Infections.Epidemiology of Multiple Herpes Viremia in Previously Immunocompetent Patients With Septic Shock.Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients.Admission Hyperglycemia in Critically Ill Sepsis Patients: Association With Outcome and Host Response.A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission.Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome*.Reply: Comprehensive Validation of the FAIM3:PLAC8 Ratio in Time-matched Public Gene Expression Data.Benzodiazepine-associated delirium in critically ill adults.Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months.Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study.Reply: FAIM3:PLAC8 Ratio Compared with Existing Biomarkers for Diagnosis of Severe Community-acquired Pneumonia: Comparing Apples to Oranges?Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort studyCorrection to: Predicting the clinical trajectory in critically ill patients with sepsis: a cohort studyPredicting the clinical trajectory in critically ill patients with sepsis: a cohort studyRobustness of sepsis-3 criteria in critically ill patients
P50
Q28606587-1A22A99E-3B94-4E96-B21A-52F0BF51EF81Q33430576-E4C8990F-B7C4-44EC-ADDE-4EEE09844FB0Q33750223-E3EC5E8A-1A06-4457-AF25-EBD816908E8FQ34220502-8617593F-B137-460C-AB94-878D0C869084Q34567596-8CD8F6E7-8EE4-48FF-851C-126B70C06174Q36035706-C86A7F4B-B140-4CC8-BD9E-63905B76624CQ36317219-93E6DF29-4C1A-48C4-95B1-E344C98D5F4BQ36564241-B0A717D6-0066-4BA2-8A12-EE3519D113B9Q36564294-09D2EF3C-D554-489B-AECB-35A180C698B3Q38127087-A2310E85-9911-4D7F-8765-36A5F33F5BCBQ38286758-3AD26D6F-2F2C-4753-BF09-E0B804F02B47Q38429232-95AD72F1-8F75-4BCA-AB59-19156CA93017Q38432516-13C71FD3-24FA-497E-A1D9-58276B392BB9Q38432917-6B1895CA-A466-454E-90F3-F3D1D7A3356CQ38435684-856DA273-5C56-436C-8641-CD9671890BD7Q38436645-3B25A6EC-99E5-499E-BC70-F6F374C5BA23Q38438969-E556561A-CE49-4EAB-A359-A85C080FAD65Q38442969-8E29B3C0-9584-4E11-AE06-66A3630C42AEQ38450738-02F216E1-267A-4CCB-A289-C6621191B8FEQ39010121-9704DD78-0D0B-4C10-9F40-0D68EDD18730Q40346711-9907DAA0-CD79-4A49-A5BE-65A1CC4935FAQ40643505-1ADB7AD8-4937-41AB-92A1-C9671CD17D99Q40762179-2C0F0E32-C383-4743-85FC-5C4268D26941Q41134628-099A29F3-8405-44B6-8392-A718432A4E96Q41673437-D0920197-EFDE-4A45-B7C7-9D87576916F5Q43688919-A1664CBA-4EAC-45CD-9AB7-223B5AD046FDQ45290249-E01856A7-EAE2-4F35-BBAA-4F025CD102ADQ48010115-BB6F12ED-73A2-4B9B-A7B8-3E587247A881Q54397911-9D3C8C09-8FD9-479E-9399-D2984D53019EQ54692896-D9BA2AD1-0C90-4131-86A8-0C4E47CEDA08Q60044180-44CE9CDD-6392-4F83-BF70-03C5F8A02A9EQ89579692-F0FE94FC-5C4B-488C-9CFB-1E2F25E96231Q91926123-14064C27-0007-417F-B82C-399930D6A962Q93136088-48192205-42F6-4CFB-8DD5-9F82F6E0E72B
P50
description
researcher (ORCID 0000-0002-8155-5336)
@en
wetenschapper
@nl
name
Peter M C Klein Klouwenberg
@en
Peter M C Klein Klouwenberg
@nl
type
label
Peter M C Klein Klouwenberg
@en
Peter M C Klein Klouwenberg
@nl
prefLabel
Peter M C Klein Klouwenberg
@en
Peter M C Klein Klouwenberg
@nl
P31
P496
0000-0002-8155-5336